Electrodiagnostic Laboratory Accreditation Program Launches Today!

The much anticipated Electrodiagnostic (EDX) Laboratory Accreditation Program is ready for its first applications. Be among the first EDX laboratories to become accredited. The program recognizes laboratories that demonstrate clinical excellence and commitment to providing the highest quality patient care. The AANEM EDX Laboratory Accreditation designation provides patients, referral sources, and payers with a credible measure of excellence. recognition will be given to the first accredited laboratory in each state. Learn more about the accreditation program, then request an application today!

Healthcare reform passes House 219-212

Last night the House passed the Senate-approved healthcare reform bill 219-212. After passing the bill, the House proceeded to approve "key changes" to it, "part of a prearranged agreement to guarantee passage of the historic legislation. The changes passed by a 220-211 vote. That bill now goes to the Senate for final approval, where it only requires a simple majority to pass. Passage in the Senate and signing by President Obama is expected to occur quickly in the next few days.

Further CMS Guidance on Consultation Services

MLN Matters® SE1010 provides further clarity from CMS for those who who perform initial E/M services previously reported by CPT consultation codes for Medicare beneficiaries and submit claims to Medicare MACs for those services. The document follows a Q&A format. It includes the first information I have seen from CMS regarding low-level inpatient consultation codes 99251 and 99252. A question on page 3 asks how services previously reported with these codes should be billed since they do not meet key requirements for 99221-99223.

AMA Morning Rounds: FDA grants orphan drug status to potential ALS treatment.

The AP (3/10) reported, "Cytokinetics Inc. said Wednesday regulators have granted 'orphan drug' status to its potential" amyotrophic lateral sclerosis, or "Lou Gehrig's disease treatment." The company also "said it plans to start a mid-stage clinical trial in the first half of this year to test the drug's effectiveness." Reuters (3/10, Sengupta) noted that the drug is called CK-2017357.

Senate votes to again delay Medicare cut

The U.S. Senate voted yesterday to delay this year's 21 percent cut in Medicare physician payments until Oct. 1. The AMA continues to call for permanent reform of Medicare's sustainable growth rate formula. "If the House adopts this Senate bill, America's seniors and their physicians will be left in limbo, and access to health care for Medicare patients will continue to be in grave danger," AMA President J. James Rohack, MD, said in a statement.

AMA Morning Rounds: FDA approves Botox to treat elbow, wrist, and finger spasms.

The AP (3/10, Perrone) reports that "the Food and Drug Administration said Tuesday it approved Allergan's...Botox [Botulinum toxin Type A] to treat spasms of the elbow, wrist and fingers." The agency "stressed in a statement that Botox is not approved to treat spasms in larger muscles of the arms or legs." In 2009, "the agency added warnings to Botox about its potential to migrate from limbs to other parts of the body, causing breathing problems."

Bloomberg News (3/10, Peterson) reports that "clinical trials showed the drug helped patients with muscle spasms in the upper limbs, Russell Katz, director of the Food and Drug Administration's Division of Neurology Products, said...in an e-mailed statement." Dow Jones Newswire (3/10, Dooren), Reuters (3/10), and HealthDay (3/9, Roberts) also covered the story.

AMA Morning Rounds: Bristol-Myers Squibb, Allergan to jointly develop drug to treat neuropathic pain

The AP (3/3) reported that "Bristol-Myers Squibb and Allergan will jointly attempt to develop a drug to treat chronic pain from tissue damage, the drugmakers said." According to the AP, "the drug is said to be ready for mid-stage human trials as a treatment for neuropathic pain, or chronic pain usually accompanied by tissue injury. It is common in people with arthritis, cancer, and nerve damage."

The Orange County Business Journal (3/3) reported that "Bristol-Myers gains the rights to develop, make and market the compound," currently known as AGN-209323, "for just about all uses except for those related to the eye, which Allergan retains." Allergan will receive "an initial payment of $40 million and potential payments of up to $373 million if the compound is successful." Reuters (3/3) and the Wall Street Journal (3/3, Becker) also covered the story.

SGR Cut Averted for 1 Month

Last night the Senate voted 78-19 to pass H.R. 4691, the "Temporary Extension Act of 2010," which included provisions to extend 2009 Medicare physician payment rates through the end of the month. As a result, the 21% payment cut that took effect on March 1 has been postponed until April 1.

The bill passed the House on February 25, only to encounter opposition on the Senate floor by Senator Jim Bunning (R-KY), who objected to the legislation being considered as an emergency measure that would not require budgetary offsets. In addition to postponing Medicare physician payment cuts, the bill extended a variety of other expiring programs including unemployment insurance and premium subsidies for COBRA continuation coverage for those whose employment was involuntarily terminated.

Discussions are still underway in the House and Senate on the next steps that will be taken to address the Medicare payment crisis. Proposals are being circulated that would implement still another short-term patch to the sustainable growth rate (SGR) formula, including proposals that would postpone cuts for 90 days, 7 months, or through the end of 2010. The AMA and those currently attending its 2010 National Advocacy Conference in Washington, DC, continue to press for permanent repeal of the SGR, rather than repeating the pattern of short-term remedies that serve to make future payment cuts more severe and increase the cost of permanent Medicare payment reform.

Members are urged to keep up the pressure, especially in the Senate, for enacting legislation to permanently resolve the Medicare physician payment crisis. Use the AMA’s Grassroots Hotline at 800-833-6354 or write an email.